ME02182B - TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN - Google Patents

TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN

Info

Publication number
ME02182B
ME02182B MEP-2015-106A MEP10615A ME02182B ME 02182 B ME02182 B ME 02182B ME P10615 A MEP10615 A ME P10615A ME 02182 B ME02182 B ME 02182B
Authority
ME
Montenegro
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
compound
intended
Prior art date
Application number
MEP-2015-106A
Other languages
English (en)
Unknown language (me)
Inventor
Mark Richard Underwood
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02182(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of ME02182B publication Critical patent/ME02182B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2015-106A 2010-01-27 2011-01-24 TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN ME02182B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
EP11737484.3A EP2531027B1 (en) 2010-01-27 2011-01-24 Therapeutic combination comprising dolutegravir, abacavir and lamivudine
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (1)

Publication Number Publication Date
ME02182B true ME02182B (me) 2015-10-20

Family

ID=44319704

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2015-106A ME02182B (me) 2010-01-27 2011-01-24 TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN
MEP-2018-131A ME03058B (me) 2010-01-27 2011-01-24 Antivirusna terapija

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2018-131A ME03058B (me) 2010-01-27 2011-01-24 Antivirusna terapija

Country Status (45)

Country Link
US (13) US20120295898A1 (cg-RX-API-DMAC7.html)
EP (6) EP3351249A1 (cg-RX-API-DMAC7.html)
JP (9) JP2013518107A (cg-RX-API-DMAC7.html)
KR (4) KR101883750B1 (cg-RX-API-DMAC7.html)
CN (2) CN105311033B (cg-RX-API-DMAC7.html)
AP (1) AP3551A (cg-RX-API-DMAC7.html)
AU (1) AU2011209788C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012018670A2 (cg-RX-API-DMAC7.html)
CA (4) CA3003988C (cg-RX-API-DMAC7.html)
CL (1) CL2012002080A1 (cg-RX-API-DMAC7.html)
CO (1) CO6602152A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120423A (cg-RX-API-DMAC7.html)
CY (6) CY1116509T1 (cg-RX-API-DMAC7.html)
DK (4) DK3494972T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2012000205A (cg-RX-API-DMAC7.html)
EA (4) EA032868B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12012106A (cg-RX-API-DMAC7.html)
ES (4) ES2969969T3 (cg-RX-API-DMAC7.html)
FI (2) FI3494972T3 (cg-RX-API-DMAC7.html)
FR (2) FR18C1043I2 (cg-RX-API-DMAC7.html)
HK (1) HK1250335A1 (cg-RX-API-DMAC7.html)
HR (4) HRP20240168T1 (cg-RX-API-DMAC7.html)
HU (6) HUE026849T2 (cg-RX-API-DMAC7.html)
IL (5) IL221007A (cg-RX-API-DMAC7.html)
LT (5) LT2932970T (cg-RX-API-DMAC7.html)
LU (2) LUC00090I2 (cg-RX-API-DMAC7.html)
MA (1) MA34002B1 (cg-RX-API-DMAC7.html)
ME (2) ME02182B (cg-RX-API-DMAC7.html)
MX (4) MX2012008774A (cg-RX-API-DMAC7.html)
MY (3) MY202778A (cg-RX-API-DMAC7.html)
NO (2) NO2932970T3 (cg-RX-API-DMAC7.html)
NZ (4) NZ627827A (cg-RX-API-DMAC7.html)
PE (2) PE20160180A1 (cg-RX-API-DMAC7.html)
PH (3) PH12012501537A1 (cg-RX-API-DMAC7.html)
PL (4) PL3494972T3 (cg-RX-API-DMAC7.html)
PT (4) PT2932970T (cg-RX-API-DMAC7.html)
RS (4) RS57728B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201707183TA (cg-RX-API-DMAC7.html)
SI (4) SI3127542T1 (cg-RX-API-DMAC7.html)
SM (4) SMT201800290T1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000376A1 (cg-RX-API-DMAC7.html)
TR (1) TR201807704T4 (cg-RX-API-DMAC7.html)
UA (1) UA105556C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011094150A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205586B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
EP2911674A1 (en) 2012-10-23 2015-09-02 Cipla Limited Pharmaceutical antiretroviral composition
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
CA2897137A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
NO2865735T3 (cg-RX-API-DMAC7.html) 2013-07-12 2018-07-21
CA2924829C (en) 2013-09-27 2019-10-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用
NO2717902T3 (cg-RX-API-DMAC7.html) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3177629B1 (en) 2014-07-29 2020-01-29 LEK Pharmaceuticals d.d. Novel hydrates of dolutegravir sodium
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
WO2019016732A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Hiv感染症及びaidsを治療するためのレジメン
EP3694522B1 (en) * 2017-10-13 2025-11-26 VIIV Healthcare Company Bi-layer pharmaceutical tablet formulation
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
AU2020358156B2 (en) 2019-10-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Method for treating HIV with cabotegravir and rilpivirine
US12678509B2 (en) 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
WO2021142150A1 (en) * 2020-01-09 2021-07-15 University Of Washington Long-acting therapeutic agent combinations and methods thereof
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
WO1999048371A1 (en) 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
KR100880550B1 (ko) 2000-01-31 2009-01-30 쿠크 바이오텍, 인코포레이티드 판막 기구 및 심장 판막 기구
SI1762567T1 (sl) 2001-04-10 2012-08-31 Pfizer Derivati pirazola za zdravljenje HIV-a
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
BR0311141A (pt) 2002-06-27 2005-06-07 Medivir Ab Interação sinergìstica de abacavir e alovudine
PT1583542E (pt) * 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1976915A (zh) * 2004-02-11 2007-06-06 史密丝克莱恩比彻姆公司 Hiv整合酶抑制剂
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
SI1742642T1 (sl) * 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
ES2358269T3 (es) 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2005305609B2 (en) 2004-09-17 2011-10-06 Idenix Pharmaceuticals, Inc. Phosphoindoles as HIV inhibitors
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
WO2006096444A2 (en) 2005-03-04 2006-09-14 Smithkline Beecham Corporation Chemical compounds
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
JP2008542352A (ja) 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のhiv感染治療薬を含む相乗作用のコンビネーション
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
US20070219243A1 (en) 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
AR059097A1 (es) * 2006-01-20 2008-03-12 Tibotec Pharm Ltd Tratamiento a largo plazo de la infeccion por vih
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
PT2069303E (pt) 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
CN101784532B (zh) 2007-06-29 2014-10-22 韩国化学研究院 Hiv逆转录酶抑制剂
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CA2711424A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
AU2008342536A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel C-21-keto lupane derivatives preparation and use thereof
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規17βルパン誘導体
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP3617194B1 (en) 2008-12-11 2023-11-08 VIIV Healthcare Company Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
SG171308A1 (en) 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
HUE065569T2 (hu) 2024-06-28
ECSP12012106A (es) 2013-05-31
WO2011094150A1 (en) 2011-08-04
JP2016145204A (ja) 2016-08-12
KR101964923B1 (ko) 2019-04-02
US20160339033A1 (en) 2016-11-24
MY207233A (en) 2025-02-07
NZ627824A (en) 2016-02-26
EA201290583A1 (ru) 2013-04-30
CY2018029I1 (el) 2019-07-10
MX356891B (es) 2018-06-19
NO2018036I1 (no) 2018-10-15
CY1121040T1 (el) 2019-12-11
KR101883750B1 (ko) 2018-07-31
IL257267A (en) 2018-03-29
TR201807704T4 (tr) 2018-06-21
DK2531027T3 (en) 2015-07-20
PT2531027E (pt) 2015-09-16
JP2021091705A (ja) 2021-06-17
ES2688925T3 (es) 2018-11-07
LT2932970T (lt) 2018-06-25
KR101830715B1 (ko) 2018-04-04
PL2531027T3 (pl) 2016-01-29
ME03058B (me) 2019-01-20
US20170281636A1 (en) 2017-10-05
RS57728B1 (sr) 2018-12-31
JP2025131664A (ja) 2025-09-09
KR20170078868A (ko) 2017-07-07
CN102791129A (zh) 2012-11-21
AU2011209788A1 (en) 2012-08-16
CA3060290C (en) 2022-07-12
MX367937B (es) 2019-09-12
HRP20181531T1 (hr) 2018-11-16
PE20121524A1 (es) 2012-12-03
EA201892277A1 (ru) 2019-03-29
US20160199379A1 (en) 2016-07-14
PL3127542T3 (pl) 2019-03-29
CY2024017I1 (el) 2025-05-09
ES2543066T3 (es) 2015-08-14
HUS2400017I1 (hu) 2024-06-28
CA2787691C (en) 2018-07-17
SMT201500177B (it) 2015-09-07
JP2023085431A (ja) 2023-06-20
CA2967453A1 (en) 2011-08-04
SMT201800290T1 (it) 2018-07-17
EP2932970A1 (en) 2015-10-21
IL281959B (en) 2021-12-01
EP4316599A3 (en) 2024-04-10
NZ627827A (en) 2016-02-26
LT3494972T (lt) 2024-03-12
MX2012008774A (es) 2012-08-17
JP6268386B2 (ja) 2018-01-31
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
CL2012002080A1 (es) 2012-11-30
HK1250335A1 (en) 2018-12-14
CN102791129B (zh) 2015-09-30
HUE037812T2 (hu) 2018-09-28
CY1120457T1 (el) 2019-07-10
EP2531027A4 (en) 2013-07-03
CY1126771T1 (el) 2025-05-09
EP3127542B1 (en) 2018-08-22
SI3127542T1 (sl) 2018-11-30
EP3494972A1 (en) 2019-06-12
AU2011209788C1 (en) 2014-08-28
IL267658A (en) 2019-08-29
CA3060290A1 (en) 2011-08-04
IL281959A (en) 2021-05-31
JP2022071126A (ja) 2022-05-13
PT3127542T (pt) 2018-11-26
SG10201707183TA (en) 2017-10-30
LTC2932970I2 (lt) 2022-04-25
RS54123B1 (sr) 2015-12-31
CA2967453C (en) 2018-07-17
PH12012501537A1 (en) 2018-02-07
LUC00346I2 (cg-RX-API-DMAC7.html) 2026-05-05
DK3494972T3 (da) 2024-01-29
FIC20240016I1 (fi) 2024-05-31
PH12016500195A1 (en) 2016-12-05
EP3494972B1 (en) 2023-12-13
NZ627826A (en) 2016-01-29
EA037601B1 (ru) 2021-04-20
EA202190473A2 (ru) 2021-06-30
HUE026849T2 (en) 2016-08-29
US20150238496A1 (en) 2015-08-27
PT2932970T (pt) 2018-06-08
RS65183B1 (sr) 2024-03-29
US20200230147A1 (en) 2020-07-23
LUC00090I2 (cg-RX-API-DMAC7.html) 2019-01-08
CA3003988A1 (en) 2011-08-04
EA201690872A3 (ru) 2016-12-30
US20170216284A1 (en) 2017-08-03
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
LTPA2018013I1 (lt) 2018-11-12
TN2012000376A1 (en) 2014-01-30
LTPA2024516I1 (cg-RX-API-DMAC7.html) 2024-06-25
EP2531027A1 (en) 2012-12-12
JP2017008087A (ja) 2017-01-12
LUC00346I1 (cg-RX-API-DMAC7.html) 2024-06-04
US20250017939A1 (en) 2025-01-16
KR20120128640A (ko) 2012-11-27
BR112012018670A2 (pt) 2018-02-06
EP4316599A2 (en) 2024-02-07
HK1209629A1 (en) 2016-04-08
IL267658B (en) 2021-04-29
AP2012006445A0 (en) 2012-08-31
IL245182A0 (en) 2016-06-30
EP3351249A1 (en) 2018-07-25
ES2969969T3 (es) 2024-05-23
AU2011209788B2 (en) 2014-02-06
CY2024017I2 (el) 2025-05-09
PL3494972T3 (pl) 2024-05-27
DK3127542T3 (en) 2018-11-12
PL2932970T3 (pl) 2018-08-31
EA025176B1 (ru) 2016-11-30
FI3494972T3 (fi) 2024-03-01
DOP2021000147A (es) 2022-01-16
US10426780B2 (en) 2019-10-01
PT3494972T (pt) 2024-02-12
PH12016500195B1 (en) 2021-08-04
EA202190473A3 (ru) 2021-12-31
MX367938B (es) 2019-09-12
HUS1800042I1 (hu) 2018-11-28
CY1116509T1 (el) 2017-03-15
CN105311033B (zh) 2019-05-07
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
US20170079982A1 (en) 2017-03-23
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
EP2932970B1 (en) 2018-03-21
JP7724619B2 (ja) 2025-08-18
MY202778A (en) 2024-05-21
SMT202400063T1 (it) 2024-03-13
PH12018502489A1 (en) 2020-06-15
DOP2012000205A (es) 2012-10-15
CO6602152A2 (es) 2013-01-18
US20180200254A1 (en) 2018-07-19
CR20120423A (es) 2012-11-22
KR20160111536A (ko) 2016-09-26
DK2932970T3 (en) 2018-05-28
KR20180078358A (ko) 2018-07-09
MY188334A (en) 2021-11-30
NZ601319A (en) 2014-08-29
FR24C1024I2 (fr) 2025-06-27
HRP20180855T1 (hr) 2018-06-29
SI3494972T1 (sl) 2024-03-29
JP2013518107A (ja) 2013-05-20
MA34002B1 (fr) 2013-02-01
CA3003988C (en) 2020-01-07
EP3127542A1 (en) 2017-02-08
US11234985B2 (en) 2022-02-01
CA2787691A1 (en) 2011-08-04
IL221007A0 (en) 2012-09-24
FR18C1043I1 (cg-RX-API-DMAC7.html) 2018-11-30
JP2019167371A (ja) 2019-10-03
LTC3494972I2 (cg-RX-API-DMAC7.html) 2025-11-10
ES2670811T3 (es) 2018-06-01
US20180098992A1 (en) 2018-04-12
HUE040554T2 (hu) 2019-03-28
HK1179522A1 (en) 2013-10-04
HRP20150770T1 (hr) 2015-08-28
SG10201509476RA (en) 2015-12-30
SI2531027T1 (sl) 2015-08-31
JP2018127473A (ja) 2018-08-16
US20210401850A1 (en) 2021-12-30
FR18C1043I2 (fr) 2019-10-11
AP3551A (en) 2016-01-18
SI2932970T1 (en) 2018-07-31
LT3127542T (lt) 2018-11-26
EP2531027B1 (en) 2015-05-06
IL245182B (en) 2018-04-30
EA201690872A2 (ru) 2016-08-31
EA032868B1 (ru) 2019-07-31
UA105556C2 (uk) 2014-05-26
NO2932970T3 (cg-RX-API-DMAC7.html) 2018-08-18
US20120295898A1 (en) 2012-11-22
US20170119777A1 (en) 2017-05-04
SMT201800594T1 (it) 2019-01-11
CN105311033A (zh) 2016-02-10

Similar Documents

Publication Publication Date Title
ME02312B (me) DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
HRP20171512T1 (hr) Derivati betulina
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
WO2015042497A3 (en) Substituted aminopyrimidine compounds and methods of use
NZ609527A (en) N1/n2-lactam acetyl-coa carboxylase inhibitors
NZ703341A (en) Compositions comprising apomorphine and organic acids and uses thereof
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
HRP20160203T1 (hr) Pripravci koji sadrže 15-hepe i postupci njihove upotrebe
WO2012048129A3 (en) Inhibitors of polo-like kinase
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
IL220318A (en) Aqueous solutions comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart diseases
ME02405B (me) Spojevi pirazola као inhibitori sglt1
HK1216839A1 (zh) 调整释放制剂
BR112012019515A2 (pt) indutor de continuação de leitura, e agente terapêutico para doenças genéticas do tipo de mutações anti-senso
EA201270653A1 (ru) Антагонист dpи его применение
JP2014518280A5 (cg-RX-API-DMAC7.html)
NZ606236A (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
WO2014045046A3 (en) Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
MX2015007885A (es) Compuestos farmaceuticos.
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon